长期雄激素剥夺治疗对去势敏感性前列腺癌患者PSMA配体PET/CT的影响
本研究回顾性分析了2011至2017年间在本机构接受68Ga-PSMA-11 PET/CT检查的1704例患者,其中10例在两次PSMA PET/CT之间开始并持续雄激素剥夺治疗(ADT)且临床持续缓解。结果显示,ADT期间(持续时间42-369天,中位230天)可见前列腺癌病灶数从31个降至14个,71%的病灶示踪剂摄取平均值下降,12.9%升高。作者推荐在开始ADT前转诊行PSMA PET/CT以显示最大范围病变。
要点
- 持续长期ADT显著降低去势敏感性前列腺癌在PSMA PET/CT上的可见性。
- ADT期间71%的前列腺癌病灶示踪剂摄取平均值下降,12.9%升高。
- 若目标是显示最大可能病变范围,作者推荐在开始ADT前转诊行PSMA PET/CT。
核心结论
- 持续长期ADT显著降低去势敏感性前列腺癌在PSMA PET/CT上的可见性。
- 若目标是显示最大可能病变范围,作者推荐在开始ADT前转诊行PSMA PET/CT。
研究设计与样本
- 回顾性分析2011至2017年间在本机构接受68Ga-PSMA-11 PET/CT检查以检测前列腺癌的全部1704例患者。
- 在至少接受两次扫描的306例患者中,10例在两次PSMA PET/CT扫描之间开始并持续ADT且临床持续缓解,纳入本分析。
- 比较开始ADT前与持续ADT期间PSMA PET/CT上前列腺癌病灶的示踪剂摄取强度和体积。
主要发现
- 全部10例患者在开始ADT前共可见31个前列腺癌病灶;持续ADT期间(持续时间42-369天,中位230天)仅8例患者可见14个病灶。
- 前列腺癌病灶中71%的示踪剂摄取平均值下降,12.9%升高。
- 在6例达到完全PSA缓解(≤0.1 ng/ml)的患者中,33.3%的病灶仍可见。
临床怎么用
- 作者推荐:若目标是显示最大可能病变范围,在开始ADT前转诊行PSMA PET/CT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Since the introduction of PSMA PET/CT with 68Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further analyse the influence of long-term ADT on PSMA PET/CT findings. METHODS: A retrospective analysis was performed of all 1,704 patients who underwent a 68Ga-PSMA-11 PET/CT scan at our institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADT with a continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during ongoing ADT. RESULTS: Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42-369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71% and increased in 12.9% of the PC lesions. Of all lesions, 33.3% were still visible in six patients with a complete PSA response (≤0.1 ng/ml). CONCLUSION: Continuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before starting ADT.
引用
- Afshar-Oromieh A, Debus N, Uhrig M, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 29980832. doi:10.1007/s00259-018-4079-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。